Search
Travere Therapeutics Inc
TVTXAdd to Watchlist
55.890USD
-1.390-2.43%
Close 07-31 16:00（ET）Quotes delayed by 15 min
5.16BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Travere Therapeutics Inc is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 41.00, with a high of 49.00 and a low of 31.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
59.615
Target Price
+7.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Travere Therapeutics Inc
TVTX
15
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Travere Therapeutics Inc's expected revenue for the next quarter?
Travere Therapeutics Inc's expected revenue is 159.59M.
What is Travere Therapeutics Inc's price target?
Analysts forecast that Travere Therapeutics Inc's price target is USD 41.00, with the highest forecast at USD 49.00 and the lowest forecast at USD 31.00.
How have Travere Therapeutics IncTVTX's recent earnings per share performed?
The market expectation was USD -0.40, while Travere Therapeutics IncTVTX's earnings per share (EPS) for the previous quarter was USD 0.03. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for Travere Therapeutics Inc?
Based on the ratings of Travere Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.